Journal article
Patient perceptions of treatment-free remission in chronic myeloid leukemia
LA Villemagne Sanchez, C O’Callaghan, K Gough, K Hall, Y Kashima, JF Seymour, P Schofield, DM Ross
Leukemia and Lymphoma | TAYLOR & FRANCIS LTD | Published : 2018
Abstract
Around half of patients with chronic myeloid leukemia (CML) who achieve a stable deep molecular response would remain in treatment-free remission (TFR) if their tyrosine kinase inhibitors (TKIs) were stopped. TFR is increasingly becoming a goal of treatment. Eighty-seven patients answered a survey exploring patient perceptions of TFR, incorporating CML-specific factors (disease history, treatment toxicity, and adherence) and questions concerning health beliefs. 81% of participants (95% CI: 72%–89%) indicated that they would be willing to attempt TFR. No demographic or CML-related variable in the survey was significantly associated with willingness. In qualitative analysis, the commonest moti..
View full abstractGrants
Awarded by Novartis Pharma
Funding Acknowledgements
Funding for data collection was provided by Novartis Pharma in the form of an unrestricted research grant to DMR.